Cargando…

Comparing end-tidal CO(2), respiration volume per time (RVT), and average gray matter signal for mapping cerebrovascular reactivity amplitude and delay with breath-hold task BOLD fMRI

Cerebrovascular reactivity (CVR), defined as the cerebral blood flow response to a vasoactive stimulus, is an imaging biomarker with demonstrated utility in a range of diseases and in typical development and aging processes. A robust and widely implemented method to map CVR involves using a breath-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zvolanek, Kristina M., Moia, Stefano, Dean, Joshua N., Stickland, Rachael C., Caballero-Gaudes, César, Bright, Molly G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266270/
https://www.ncbi.nlm.nih.gov/pubmed/36958618
http://dx.doi.org/10.1016/j.neuroimage.2023.120038
Descripción
Sumario:Cerebrovascular reactivity (CVR), defined as the cerebral blood flow response to a vasoactive stimulus, is an imaging biomarker with demonstrated utility in a range of diseases and in typical development and aging processes. A robust and widely implemented method to map CVR involves using a breath-hold task during a BOLD fMRI scan Recording end-tidal CO(2) (P(ET)CO(2)) changes during the breath-hold task is recommended to be used as a reference signal for modeling CVR amplitude in standard units (%BOLD/mmHg) and CVR delay in seconds. However obtaining reliable P(ET)CO(2) recordings requires equipment and task compliance that may not be achievable in all settings. To address this challenge, we investigated two alternative reference signals to map CVR amplitude and delay in a lagged general linear model (lagged-GLM) framework: respiration volume per time (RVT) and average gray matter BOLD response (GM-BOLD). In 8 healthy adults with multiple scan sessions, we compare spatial agreement of CVR maps from RVT and GM-BOLD to those generated with P(ET)CO(2). We define a threshold to determine whether a P(ET)CO(2) recording has “sufficient” quality for CVR mapping and perform these comparisons in 16 datasets with sufficient P(ET)CO(2) and 6 datasets with insufficient P(ET)CO(2). When P(ET)CO(2) quality is sufficient, both RVT and GM-BOLD produce CVR amplitude maps that are nearly identical to those from P(ET)CO(2) (after accounting for differences in scale), with the caveat they are not in standard units to facilitate between-group comparisons. CVR delays are comparable to P(ET)CO(2) with an RVT regressor but may be underestimated with the average GM-BOLD regressor. Importantly, when P(ET)CO(2) quality is insufficient, RVT and GM-BOLD CVR recover reasonable CVR amplitude and delay maps, provided the participant attempted the breath-hold task. Therefore, our framework offers a solution for achieving high quality CVR maps in both retrospective and prospective studies where sufficient P(ET)CO(2) recordings are not available and especially in populations where obtaining reliable measurements is a known challenge (e.g., children). Our results have the potential to improve the accessibility of CVR mapping and to increase the prevalence of this promising metric of vascular health.